Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 16/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.60 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.60 |
| ▸ | EGFR | P00533 | 2/20 | 0.60 |
| ▸ | FYN | P06241 | 2/20 | 0.60 |
| ▸ | HCK | P08631 | 2/20 | 0.60 |
| ▸ | SRC | P12931 | 2/20 | 0.60 |
| ▸ | JAK3 | P52333 | 2/20 | 0.60 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.60 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.60 |
| ▸ | YES1 | P07947 | 1/20 | 0.60 |
| ▸ | LYN | P07948 | 1/20 | 0.60 |
| ▸ | FGR | P09769 | 1/20 | 0.60 |
| ▸ | KIT | P10721 | 1/20 | 0.60 |
| ▸ | BCR | P11274 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL774458 | 0.92 | LCK (0.62) | LCKMAPK14MAPK13EGFRFYN | |
| SCHEMBL6000502 | 0.85 | LCK (0.64) | LCKMAPK14MAPK13EGFRFYN | |
| SCHEMBL773909 | 0.84 | LCK (0.68) | LCKMAPK14MAPK13EGFRFYN | |
| SCHEMBL14569074 | 0.84 | LCK (0.75) | LCKMAPK14MAPK13EGFRFYN | |
| SCHEMBL1540977 | 0.82 | LCK (0.70) | LCKMAPK14MAPK13EGFRFYN | |
| SCHEMBL771868 | 0.82 | LCK (0.70) | LCKMAPK14MAPK13EGFRFYN | |
| SCHEMBL14569092 | 0.82 | LCK (0.70) | LCKMAPK14MAPK13EGFRFYN | |
| SCHEMBL773039 | 0.81 | LCK (0.61) | LCKMAPK14MAPK13EGFRFYN | |
| SCHEMBL15891879 | 0.81 | LCK (0.68) | LCKMAPK14MAPK13EGFRFYN | |
| SCHEMBL19390257 | 0.81 | LCK (0.82) | LCKMAPK14MAPK13EGFRFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190210986-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210986-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | LCK, ABL1, BTK | LCK 1/4885MAPK14 183/4885MAPK13 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.